Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Eleven arrested over mass shooting in South Africa tavern - 2Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- 3Idris Elba is the king of the stress-watch
- 4Instructions to Plan for Your Teeth Substitution Methodology
- 5Instructions to Back Your Sunlight powered chargers: Tracking down Possible Choices
- Underestimated Metropolitan Experience Urban communities On the planet
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- Experiences in Natural life Protection: Individual Progressives' Excursions
- The Best Cell phone Brands for Tech Lovers
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget
- Bayer reports positive results for blood thinner after 2023 setback
